NCT07030712View on ClinicalTrials.gov

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

PHASE1RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

August 23, 2027

Study Completion Date

August 23, 2027

Conditions
Metastatic Neoplasm
Interventions
DRUG

MK-8294

30 µg via intravenous (IV) infusion

DRUG

MK-8294

100 µg via intravenous (IV) infusion

DRUG

MK-8294

300 µg via intravenous (IV) infusion

DRUG

MK-8294

1 mg via intravenous (IV) infusion

DRUG

MK-8294

3 mg via intravenous (IV) infusion

DRUG

MK-8294

10 mg via intravenous (IV) infusion

DRUG

MK-8294

30 mg via intravenous (IV) infusion

DRUG

MK-8294

70 mg via intravenous (IV) infusion

Trial Locations (4)

60611

RECRUITING

Northwestern University ( Site 0101), Chicago

3109601

RECRUITING

Rambam Health Care Campus ( Site 0201), Haifa

5265601

RECRUITING

Sheba Medical Center ( Site 0200), Ramat Gan

1066 CX

RECRUITING

Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300), Amsterdam

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY